- Trial phase
- Approved (marketed); Phase 3 readout pending in aHUS
- Time to market
- Already on the market (approved per FDA catalyst record dated 2023-12-05); potential aHUS label expansion depends on the pending Phase 3 readout and a future regulatory filing.
- Why 4/10
- Fabhalta is already approved and commercializing (FDA approval catalyst recorded 2023-12-05), so there is no pending PDUFA on the approved indication; the only near-term hard catalyst is the Phase 3 aHUS topline readout (trial NCT04889430 completed 2026-04-11, results flagged "imminent" in July 2026), a binary within ~6 months, but a 34-patient niche trial at a mega-cap where Fabhalta is a minor value driver, so the score stays at 4.
Watch for the pending Phase 3 aHUS (atypical hemolytic uremic syndrome) topline readout from trial NCT04889430, which completed April 11, 2026 and was flagged "results pending, data readout imminent" in the local events ledger, a positive result could support a label-expansion filing, but the trial is only ~34 patients and Fabhalta is one product inside a ~$200B mega-cap, so expect only a modest NVS move. Also monitor Novartis quarterly commentary on Fabhalta sales ramp and any follow-on safety labeling after the June 2026 boxed-warning update.
Price Chart
Executive Summary
Fabhalta (iptacopan) is Novartis's first-in-class oral complement Factor B inhibitor; local FDA data confirm it as a Novartis product (NDA 218276, oral route) with an FDA approval catalyst recorded on Dec 5, 2023 (the widely reported PNH approval) and a June 8, 2026 safety-labeling update adding a boxed warning for serious infections from encapsulated bacteria. Its next major catalyst is the pending Phase 3 readout in aHUS (NCT04889430), completed April 2026 with results not yet posted. For NVS, a mega-cap trading at ~$156 with a mean analyst target near $157, Fabhalta is a genuine growth asset but a small slice of value, so even its binary catalysts move the stock modestly.
How It Works
Fabhalta (iptacopan) is an oral (pill) drug that blocks "Factor B," a protein in the complement system, part of the immune system that, when overactive, attacks the body's own red blood cells and kidneys. By dialing down that attack, it treats complement-driven blood and kidney diseases without the IV infusions used by older complement inhibitors.
Trial Status
FDA approval catalyst recorded 2023-12-05 for FABHALTA (NVS). A Phase 3 trial of iptacopan (LNP023) in complement-inhibitor-naive adult aHUS patients (NCT04889430, 34 enrolled, sponsor Novartis Pharmaceuticals) reached primary completion on 2026-04-11 with status COMPLETED; results have NOT yet been posted, and the local events ledger flagged "Results Pending, data readout imminent" (last flagged ~86 days post-completion in early July 2026). FDA safety labeling was updated 2026-06-08 adding a boxed warning on serious encapsulated-bacteria infections (a complement-inhibitor class effect).
The Two-Sided Case
Upcoming Catalysts
- Phase 3 aHUS topline readout for iptacopan (NCT04889430), flagged 'results pending / imminent' as of July 2026; no exact date announced.
- Potential aHUS regulatory filing if the readout is positive.
- Novartis quarterly earnings commentary on Fabhalta sales ramp and franchise outlook.
- Any follow-on safety-labeling or regulatory communications after the June 2026 boxed-warning update.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVARTIS AG 6-K NVS ·Originating report